BioNTech Se (NASDAQ: BNTX) Share Price and News

$99.72 $-3.84 (-3.7%) Saturday, 16 November 2024 at 8:00:00 am Australian Eastern Daylight Time

BioNTech Se Chart and Price Data

About BioNTech Se

Last updated 16-11-2024, 08:00:00am AEDT
Current Price $99.72
Change $-3.84 (-3.7%)
Close Price $99.72
Open Price $99.89
Bid $97.00
Ask $99.90
Day Range $94.31 - $101.65
Year Range $76.53 - $131.49
Volume 3,377,161
Average Volume 1,063,228
Market Cap $23,906,872,800.00
Earnings Per Share $-2.15
  • BioNTech Se (NASDAQ: BNTX)
    Latest News

    Share Market News

    Dow Jones hits new record highs. Are ASX 200 shares next?

    The Dow Jones just hit new all-time highs. ASX 200 shares are still 9% below their record highs, but that…

    Read more »

    Group of young friends wearing facemasks dining out and raising glasses in a toast
    Coronavirus News

    COVID-19 over? Credit and debit card spend surges

    Commonwealth Bank research shows Australians have started splashing the dollars around. Is the coronavirus recession over?

    Read more »

    A hand holding a pin about to burst a balloon, indicating a crash or drop in asx shares
    Share Market News

    Will Pfizer's COVID-19 vaccine end the ASX tech share rally?

    With Pfizer's announcement of a promising COVID-19 vaccine, ASX tech shares are largely missing out on the global share market…

    Read more »

    International Stock News

    Pfizer and BioNTech coronavirus vaccine accepted for rolling review in Canada

    Health Canada will determine BNT162b2's suitability for approval as clinical trial data comes in.

    Read more »

    person receiving coronavirus vaccine injection into the arm
    International Stock News

    3 reasons Pfizer and BioNTech will have coronavirus vaccine data before Moderna

    Different clinical trial designs gives the duo an advantage, but coming in first isn't the end goal for vaccine makers.

    Read more »

    doctor giving little boy vaccine injection in his arm
    International Stock News

    Johnson & Johnson (NYSE:JNJ) starts late-stage coronavirus vaccine clinical trial

    The phase 3 study of JNJ-78436735, which will enroll 60,000 participants, is underway.

    Read more »

    gloved hand injecting coronavirus vaccine into person's arm
    International Stock News

    Coronavirus vaccine trial adverse event was probably unrelated to treatment

    The paused clinical trial has already resumed.

    Read more »

    International Stock News

    Pfizer says it could know if its COVID-19 vaccine candidate works in October

    The drugmaker's CEO said there was a more than 60% chance that they would know by the end of next…

    Read more »

    doctor making thumbs up gesture and holding vial labelled 'covid-19 vaccine' representing covid shares
    International Stock News

    The surefire vaccine winner following AstraZeneca's COVID-19 trial pause

    Hint: It's not Moderna.

    Read more »

    International Stock News

    What if more than one company wins the coronavirus vaccine race?

    The ability to globally distribute a vaccine is as important as the vaccine itself. To the best-equipped victors go the…

    Read more »

    CSL share price represented by hand in blue glove picks out a vial labelled 'covid-19 vaccine' from a row of vials
    International Stock News

    Coronavirus vaccine race: 7 key things you'll want to know

    Here are the answers to your top questions about where things stand with the development of COVID-19 vaccines.

    Read more »

    Patient wearing mask gets COVID vaccine injection
    International Stock News

    AstraZeneca coronavirus vaccine clinical trial paused

    One participant fell ill, but the connection to treatment with AZD122 is unclear.

    Read more »

    Profile

    since

    Note